For species that rely on sexual reproduction, including mice and men, offspring can only happen if sperm from the male fertilize eggs from the female. Even artificial fertilization techniques depend on donors for both of these cells. However, a new study led by researchers from ASHBi (ASHBi Institute for the Advanced Study of Human Biology […]
https://interhospi.com/wp-content/uploads/sites/3/2021/11/sperm-cells.jpg9101624panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-11-04 12:13:022021-11-04 12:13:02Scientists make sperm from mouse pluripotent stem cells, produce healthy offspring
Extremely premature infants are at a high risk for brain damage. Researchers at the University of Vienna and the Medical University of Vienna have now found possible targets for the early treatment of such damage outside the brain: Bacteria in the gut of premature infants.
https://interhospi.com/wp-content/uploads/sites/3/2021/11/gut_bacteria_brain.jpg484848panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-11-04 12:08:062021-11-04 12:08:06Researchers find biomarkers in gut microbiome indicate early brain injury in extreme premature infants
For the first time, researchers at the Technical University of Munich (TUM) have successfully used a new X-ray method for respiratory diagnostics with patients. Dark-field X-rays visualize early changes in the alveolar structure caused by the lung disease COPD and require only one fiftieth of the radiation dose typically applied in X-ray computed tomography. This permits broad medical application in early detection and treatment follow-up of respiratory ailments.
There are millions of cases in which serious respiratory system illnesses place limitations on quality of life. Every year more than four million people die of serious respiratory ailments worldwide. Partially destroyed alveoli and an over-inflation of the lungs (emphysema) are typical of the life-threatening ailment Chronic Obstructive Pulmonary Disease (COPD).
However, the fine distinctions between healthy and diseased tissue are barely visible on conventional chest X-rays. Detailed diagnostic information is only available using three-dimensional computed tomography approaches, in which the computer assembles many individual images. Until now there has been no fast and cost-effective option for early detection and follow-up examinations with a low radiation exposure as used in plain chest X-rays.
A procedure developed at the Technical University of Munich could now fill this gap: dark-field chest X-rays. In the November 1, 2021 issue of The Lancet Digital Health a research team led by Franz Pfeiffer, Professor for Biomedical Physics and Director of the Munich Institute of Biomedical Engineering at TUM, present the results of an initial clinical patient study, which used the new X-ray technology for the diagnosis of the lung disease COPD.
The wave character of X-rays is the key
Conventional X-ray imaging is based on the attenuation of X-rays on their way through the tissue. Dark-field technology on the other hand use the wave nature of X-ray light, which is discarded in conventional X-ray imaging.
The new method thus uses the physical phenomenon of scattering in a manner similar to the long-known principle of dark-field microscopy with visible light. This allows to visualize the structure of objects that are for the most part transparent. These structures appear in the microscope as bright images on a dark background, which has given the method its name.
“The X-ray dark-field signal is particularly strong for interfaces between air and tissue,” Prof. Pfeiffer points out. “This makes it possible for a dark-field X-ray image of the lung to clearly distinguish between intact alveoli, i.e. those filled with air, and regions in which less intact alveoli exist.”
The dark field X-ray method visualizes early changes in the alveolar structure as a result of the lung disease COPD. Franz Pfeiffer, Professor for Biomedical Physics, hopes that this will significantly improve the early detection of lung diseases.
Lower radiation dose
In addition, an examination using dark-field chest X-ray technology involves a significantly lower radiation dose than presently used computed tomography. This is because dark-field chest X-rays require only one exposure per patient, as compared to the large number of individual images taken from different directions which are necessary in computed tomography.
“We expect the radiation exposure to be reduced by a factor of fifty,” says Prof. Pfeiffer. Furthermore, the first clinical results have confirmed that the dark-field X-rays provide additional image information on the underlying microstructure of the lung.
“Given the close connection between the alveolar structure and the functional condition of the lung, this ability is of great significance for pulmonary medicine,” explains Dr. Alexander Fingerle, senior physician at TUM’s university hospital Klinikum rechts der Isar’s Department of Diagnostic and Interventional Radiology. “In the future dark-field X-rays could help improve early detection of COPD and other respiratory ailments.”
Better X-ray equipment for early detection
Prof. Pfeiffer hopes these initial clinical results with patients will accelerate the execution of further clinical studies and the development of marketable devices that use the dark-field method.
“Dark-field chest X-rays are currently giving us a chance to significantly improve the early detection of lung diseases and at the same time to implement it on a wider basis than before,” Prof Pfeiffer notes.
Since dark-field imaging is not limited to COPD, further translational studies with other pulmonary pathologies such as pulmonary fibrosis, pneumothorax, lung cancer and pneumonia, including COVID-19, are of great interest.
Reference:
K. Willer, et. al. X-ray dark-field chest imaging for detection and quantification of emphysema in patients with chronic obstructive pulmonary disease: a diagnostic accuracy study. The Lancet Digital Health. November 1, 2021. doi: https://doi.org/10.1016/S2589-7500(21)00146-1
The International Hospital Federation (IHF) and Africa Healthcare Federation (AHF) have entered into a partnership to increase the participation of healthcare leaders from African countries in the IHF and other global hospital and healthcare initiatives.
Owlstone Medical, a global leader in breath biopsy for applications in early disease detection and precision medicine, closed its Series D financing round after securing $58 million in funding, exceeding its $50 million target after it was over subscribed. This brings the total raised by the company to more than $150 million since founding in […]
https://interhospi.com/wp-content/uploads/sites/3/2021/11/owlstone-breat-biopsy.png570520panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-11-04 08:43:382021-11-04 08:43:38Owlstone Medical secures $58 million to advance breath biopsy
A ground-breaking regional anaesthesia device, invented by clinicians at The Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust (QEH) and developed in conjunction with medical device company Medovate, has been awarded ‘Patient Safety Innovation of the Year’ at this year’s HSJ Patient Safety Awards.
https://interhospi.com/wp-content/uploads/sites/3/2021/11/Medovate-scaled.jpg17062560panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-11-04 08:41:302021-11-04 08:41:30SAFIRA regional anaesthesia device awarded HSJ Patient Safety Innovation of the Year
Brooks Automation and Cleveland Clinic have opened a new 22,000-square-foot biospecimen sample management and repository facility on Cleveland Clinic’s main campus in Cleveland, Ohio. The two-story biorepository is managed by Azenta Life Sciences, Brooks’ recently re-branded life sciences division, and includes ultra-cold and cryogenic storage. The new facility increases biobanking capacity at Cleveland Clinic and […]
Healthcare professionals create and update hundreds of thousands of patient notes, diagnostic reports, lab analyses, and other clinical records every day. Yet 80% of the data included in them is unstructured. Information about clinical diagnoses is reported using different expressions, terms, acronyms and even languages, making records impossible to consolidate, analyse and report on at […]
https://interhospi.com/wp-content/uploads/sites/3/2021/11/Jacob_Boye_Hansen-1-scaled.jpg25601707panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-11-04 08:28:182021-11-04 08:28:18DNV and CareCom launch CareIndexing: a new company shaping up disorderly clinical data with artificial intelligence
Hologic, a global leader in women’s health, will acquire Bolder Surgical, a privately held, U.S.-based company that provides advanced energy vessel sealing surgical devices, for approximately $160 million, subject to working capital and other customary closing adjustments.
https://interhospi.com/wp-content/uploads/sites/3/2021/11/hologic_logo-1.png8601878panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-11-04 08:21:002021-11-04 08:23:25Hologic to acquire Bolder Surgical for $160 million
Study that included introducing deliberate mask ‘leak’ shows this procedure is low risk and should not be used as a reason to delay or slow down surgery
New research published in Anaesthesia [1] says that the use of facemask ventilation during routine surgery should not be classed as an aerosol-generating procedure and does not increase the risk of COVID-19 transmission compared with normal breathing/coughing of patients.
Thus this procedure is not high risk and can be performed confidently for both routine surgery and emergency airway management. Its use should neither slow down operations or necessitate the use of extra personal protective equipment for medical teams.
Designation as ‘aerosol-generating procedure’
Facemask ventilation is an essential intervention used by anaesthetists as part of the ‘life support’ of most anaesthetised patients having surgery. Its designation as an ‘aerosol-generating procedure’ (AGP) by the World Health Organization has had a major impact on operating theatre efficiency and processes. However, there is no direct evidence to indicate whether facemask ventilation is a high-risk procedure for aerosol generation. No study to date has measured the aerosol generated during facemask ventilation and the evidence for its AGP classification is based largely on one study of infections in anaesthetists dating back to the previous SARS-1 epidemic in 2003.
As a result of this AGP designation, current guidance dictates that anaesthetists performing facemask ventilation in a patient at risk of having COVID-19 would have to wear a respirator mask, eye protection and additional personal protective equipment. This would also apply to nearby theatre staff. In addition, extra time (up to half an hour per case) had to be added to each operation to allow sufficient air changes in theatre to remove any of the presumed infectious aerosol. This greatly reduces the number of cases that can be done each day, especially for urgent or emergency surgery, and is contributing to the backlog in the healthcare system.
The study
In this new study, the authors conducted aerosol monitoring in anaesthetised patients during standard facemask ventilation, and facemask ventilation with an intentionally generated air leak – to mimic the worst-case scenario where aerosol might spread into the air. Recordings were made in ultraclean operating theatres (at Southmead Hospital, North Bristol NHS Trust, UK) and compared against the aerosol generated by each patient’s normal breathing and coughing.
Respiratory aerosol from normal breathing was reliably detected above the very low background particle concentrations with median aerosol concentration of 191 particles per litre. The average aerosol concentration detected during facemask ventilation without a leak (3 particles per litre) was 64-times less than that for breathing. When an intentional leak was introduced the aerosol count was 17 times lower than breathing (11 particles per litre).
When looking at peak particle concentrations the team found that a patient coughing produced a spike of 1260 particles per litre, compared to the peak of 60 per litre (20 times lower) for regular facemask ventilation and 120 per litre with an intentional leak introduced (10 times lower).
Dr Andrew Shrimpton, the lead author of the study, commented: “This study demonstrates that facemask ventilation, even when performed with an intentional leak, does not generate high levels of bioaerosol.”
The authors add: “The low concentration of aerosol detected during facemask ventilation even with an intentional leak is also reassuring given that this represents a worst-case scenario. Both normal breathing and a voluntary cough generate many-fold higher quantities of aerosol than facemask ventilation. On this basis, we believe facemask ventilation should not be considered an aerosol-generating procedure. Accumulating evidence demonstrates many procedures currently defined as aerosol-generating are not intrinsically high risk for generating aerosol, and that natural patient respiratory events often generate far higher amounts.”
Clinical guidance
They conclude: “The emerging evidence from quantitative clinical aerosol studies is yet to be incorporated into clinical guidance for aerosol-generating procedures and we believe this needs urgent reassessment. Declassification of some of these anaesthesia-related procedures as aerosol-generating would seem appropriate due to their lack of aerosol generation. Our findings also raise the broader question of whether the term ‘aerosol-generating procedure’ is still a useful concept for anaesthetic airway management practice in the prevention of SARS-CoV-2 or other airborne pathogens.”
Dr Mike Nathanson, President of the Association of Anaesthetists said: “This important work will allow clinicians to better understand the risks of general anaesthesia in patients with Covid. As we enter another winter, and with a high prevalence of Covid, the backlog of surgical cases is increasing. Anaesthetists will wish to carry on working for as many of their patients as possible. As the authors suggest, this research will inform the debate on how we can work safely.”
This study is the result of a collaboration between Anaesthetic and Aerosol research groups based in Bristol, UK and Melbourne, Australia as part of the NIHR funded AERATOR study. The results reinforce the findings of similar studies performed by the AERATOR group demonstrating many anaesthetic procedures are not high risk for aerosol generation.
Reference:
[1] Quantitative evaluation of aerosol generation during manual facemask ventilation. A. J. Shrimpton, et al. Anaesthesia. 26 October 2021. doi: https://doi.org/10.1111/anae.15599
https://interhospi.com/wp-content/uploads/sites/3/2021/10/anesthesia-mask.jpg10661280panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-10-27 09:16:322021-10-27 09:16:32New study finds facemask ventilation of patients for surgery does not increase the risk of spread of COVID-19
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.